Associated Papers
Inhibitor repurposing reveals ALK, LTK, FGFR, RET and TRK kinases as the targets of AZD1480.
Gudernova I et al.
Oncotarget, 2017
Prevalence of Mutations in Discoidin Domain-Containing Receptor Tyrosine Kinase 2 (DDR2) in Squamous Cell Lung Cancers in Korean Patients.
Lee MS et al.
Cancer Research and Treatment, 2017
Characterization of DDR2 Inhibitors for the Treatment of DDR2 Mutated Nonsmall Cell Lung Cancer.
Terai H et al.
Acs Chemical Biology, 2015
Discoidin domain receptor 2 signaling networks and therapy in lung cancer.
Payne LS et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer, 2014
Acquired resistance to dasatinib in lung cancer cell lines conferred by DDR2 gatekeeper mutation and NF1 loss.
Beauchamp EM et al.
Molecular Cancer Therapeutics, 2014
Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer.
Hammerman PS et al.
Cancer Discovery, 2011
Select a paper to view details